Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Maraviroc: a review of its use in HIV infection and beyond.

Drug design, development and therapy - 1 Jan 2015

Woollard Shawna M, Kanmogne Georgette D

Abstract excerpt

The human immunodeficiency virus-1 (HIV-1) enters target cells by binding its envelope glycoprotein gp120 to the CD4 receptor and/or coreceptors such as C-C chemokine receptor type 5 (CCR5; R5) and C-X-C chemokine receptor type 4 (CXCR4; X4), and R5-tropic viruses predominate during the early stages of infection. CCR5 antagonists bind to CCR5 to prevent viral entry. Maraviroc (MVC) is the only CCR5 antagonist...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV Infections
Share to Triazoles
Share to Anti-Inflammatory Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CCR5 Receptor Antagonists

Share to Cyclohexanes

Share to Drug Interactions

Share to Drug Resistance, Viral

Share to HIV Fusion Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 26491256
DOI: 10.2147/DDDT.S90580
PMCID: PMC4598208

Genes

CCR5
CXCR4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Maraviroc: a review of its use in HIV infection and beyond.PMID 26491256Read ↗

A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.Semantic proximity Read ↗

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.Semantic proximity Read ↗

Molecular Gymnastics: Mechanisms of HIV-1 Resistance to CCR5 Antagonists and Impact on Virus Phenotypes.Semantic proximity Read ↗

Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists.Semantic proximity Read ↗

Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.Semantic proximity Read ↗

In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.Semantic proximity Read ↗

Pharmacological advances in anti‐retroviral therapy for human immunodeficiency virus‐1 infection: A comprehensive reviewSemantic proximity Read ↗

Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice.Semantic proximity Read ↗

Small-Molecule Antagonists of CCR5 and CXCR4: A Promising New Class of Anti-HIV-1 DrugsSemantic proximity Read ↗

Therapy of HIV Infection: Current Approaches and ProspectsSemantic proximity Read ↗

Development of Anti-HIV Therapeutics: From Conventional Drug Discovery to Cutting-Edge TechnologySemantic proximity Read ↗

Antiretroviral Therapy in the ClinicSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.